Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.
Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U; NCIC-CTG; NSGO; AGO-OVAR; GOG; ANZGOG; EORTC; GEICO; JGOG; GINECO; MRC/NCRI; SGCTG; RTOG; NCI-US. Stuart G, et al. Among authors: verheijen r. Ann Oncol. 2005;16 Suppl 8:viii36-viii38. doi: 10.1093/annonc/mdi965. Ann Oncol. 2005. PMID: 16239235 Free article. No abstract available.
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).
du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC. du Bois A, et al. Among authors: verheijen r. Ann Oncol. 2005;16 Suppl 8:viii7-viii12. doi: 10.1093/annonc/mdi961. Ann Oncol. 2005. PMID: 16239238 Free article. No abstract available.
Clinical trials in ovarian carcinoma: study methodology.
Vermorken JB, Parmar MK, Brady MF, Eisenhauer EA, Hogberg T, Ozols RF, Rochon J, Rustin GJ, Sagae S, Verheijen RH; Gynecologic Cancer Intergroup; EORTC; MRC/NCRI; GOG; NCIC-CTG; NSGO; AGO-OVAR; JGOG. Vermorken JB, et al. Among authors: verheijen rh. Ann Oncol. 2005;16 Suppl 8:viii20-viii29. doi: 10.1093/annonc/mdi963. Ann Oncol. 2005. PMID: 16239233 Free article. No abstract available.
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators. Vergote I, et al. Among authors: verheijen r. Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413383
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Vergote I, et al. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806. N Engl J Med. 2010. PMID: 20818904 Free article. Clinical Trial.
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial.
Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, Reed NS, Verheijen RH, Gaarenstroom KN, Mosgaard B, Seoane JM, van der Velden J, Lotocki R, van der Graaf W, Penninckx B, Coens C, Stuart G, Vergote I. Verleye L, et al. Among authors: verheijen rh. Eur J Cancer. 2011 Jan;47(1):57-64. doi: 10.1016/j.ejca.2010.08.008. Epub 2010 Sep 16. Eur J Cancer. 2011. PMID: 20850296 Clinical Trial.
Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group. Despierre E, et al. Among authors: verheijen r. Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089. Int J Gynecol Cancer. 2014. PMID: 24557434
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Van den Brande J, Nannan Panday VR, Hoekman K, Rosing H, Huijskes RV, Verheijen RH, Beijnen JH, Vermorken JB. Van den Brande J, et al. Among authors: verheijen rh. Am J Clin Oncol. 2001 Aug;24(4):401-3. doi: 10.1097/00000421-200108000-00020. Am J Clin Oncol. 2001. PMID: 11474273
328 results